Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Code of Conduct under SEBI (PIT) Regulations, 2015
Updated Strides'' Code of Practices and Procedure for Fair Disclosure of Unpublished Price Sensitive Information'' Strides Pharma Science Ltd - 532531 - Intimation Under SEBI (Prohibition Of Insider Trading) Regulations, 2015 (SEBI PIT Regulations)
Updated ''Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information'' Strides Pharma Science Ltd - 532531 - Submission Of Statement Of Deviation/ Variation Pursuant To Regulation 32 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Submission of Statement of Deviation/ Variation pursuant to Regulation 32 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Q1FY24 Quarterly Result Announced for Strides Pharma Science Ltd.
Pharmaceuticals company Strides Pharma Science announced Q1FY24 results: Reports quarterly sales of Rs 9,320 million in Q1FY24, down 1% YoY Q1FY24 gross margins at 58.7%, absolute gross margin increase of Rs 729 million YoY Consolidated EBITDA at Rs 1,686 million, up 100%+ YoY with healthy EBITDA margin expansion Significant optimization of operating costs resulted in improved operating leverage Key businesses deliver steady performance, and cost control measures yielding results Levers in place to deliver a strong performance in FY24 with improved profitability and a stronger balance sheet Arun Kumar, Founder, Managing Director, and Executive Chairperson, commented on the performance and said, “We are pleased to report a strong start to FY24, with Q1FY24 EBITDA reaching historical highs. Our focus on profitability and efficiency is witnessed in the results as we expanded EBITDA margins by 200 bps QoQ and generated strong operating cash flows. We are on track to achieve the targets we set out for FY24 at the beginning of this year on all financial parameters. The Regulated markets grew by 25% YoY with the US growing by 32% YoY and Other Regulated markets growing by 15% YoY. The growth is driven by a disciplined approach to product launches and sustainable market share on existing products. The emerging markets' performance had a slow start and is expected to gain traction during the year. We are confident of sustaining the momentum in performance driven by continuous improvement in the quality of business and delivering a strong cash generation going forward.” Result PDF Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Scheme of Arrangement
Intimation of Scheme of Amalgamation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Strides reports highest ever EBITDA, INR 1,686m in Q1FY24 Strides Pharma Science Ltd - 532531 - Outcome Of Board Meeting - Un-Audited Financial Results (Standalone & Consolidated) For Quarter Ended June 30, 2023
Outcome of Board Meeting - Un-audited Financial Results (Standalone & Consolidated) for quarter ended June 30, 2023. Strides Pharma Science Ltd - 532531 - Shareholder Meeting / Postal Ballot-Scrutinizer"s Report
Voting Results of Postal Ballot along with Scrutinizer''s Report Strides Pharma Science Ltd - 532531 - Shareholder Meeting / Postal Ballot-Outcome of Postal Ballot
Voting Results of Postal Ballot along with Scrutinizer Report Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Earnings Call for discussion of un-audited financial results for the quarter ended June 30, 2023.